SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone

Event · Earnings
Also in this documentGuidance · reaffirm

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 1, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SINT
Bullish
high confidence
Mentioned
$SINT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SINTBullishMed
01

Why it matters

The preliminary revenue beat could trigger short‑term buying as investors react to the surprise and the upcoming warrant call.

02

Market read

First report of revenue exceeding guidance for a micro‑cap biotech/industrial firm; modest but actionable for short‑term traders.

03

What to watch

Potential dilution from warrant exercise and reliance on industrial contracts could temper enthusiasm.

Relevance 7/10Novelty 6/10Timing: today

Background

Sintx Technologies filed an 8‑K reporting preliminary Q3 results and reaffirming its Q4 guidance.

Company-level read

Ticker impact

$SINTBullishHigh confidence
Context

Preliminary Q3 revenue of $2.2M exceeds the high end of guidance, reaffirming Q4 guidance and triggering Class B warrant call rights.

Expected impact

likely modest upside as the market prices in the beat and warrant call potential

Evidence & confidence

First disclosure of unaudited revenue that tops guidance; small micro‑cap but material for traders seeking early moves.

Market effects

May boost sentiment for advanced ceramics and biomedical materials sector.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact beyond niche industrial and medical device markets.

Counterpoint

Revenue size remains modest; the beat may be priced in quickly, limiting upside.

Key entities

  • Sintx Technologies, Inc.

    Advanced ceramics and biomaterials developer.

Related articles

$SINTMed

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon

$SINTLow

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives SALT LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a

$SINTLow

Sintx Technologies (NASDAQ:SINT) Given “Buy” Rating at Maxim Group

Maxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.